DexCom's revised FY24 sales guidance in the Q2 earnings call led to a $18bn valuation reset. Read why I think DXCM stock is a ...

Tandem Diabetes TNDM is gaining from continued product innovations. Yet, ongoing macroeconomic challenges and tough ...

DexCom, Inc. (DXCM) Securities Class Action: DexCom, a leading provider of continuous glucose monitoring systems, is under intense scrutiny from investors and analysts following a disappointing ...

Real-world data showed reductions in healthcare resource utilization and improved glycemic control over 1 year with ...

Continuous glucose monitoring, compared with fingerstick tests, was feasible and accurate in an inpatient setting among patients and nurses.

The t:slim X2 pump is currently cleared for use with Humalog and Novolog/NovoRapid U-100 insulins globally, and Admelog/Insulin lispro Sanofi and Trurapi/Insulin aspart Sanofi U-100 insulins in Canada ...

Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of ...

Eversense 365 cleared in the U.S. as an integrated continuous glucose monitoring (iCGM) system for people with diabetes With a single sensor, the Eversense 365 system provides one year of use, versus ...

Time spent above, not below, the target glucose range was associated with mortality in a study of adults with type 2 diabetes ...

For once, you don’t have to wait a year to get the best new features from the iPhone 16 Pro. The iPhone 16 offers all the ...

Dexcom (Nasdaq:DXCM) today announced a collaboration to establish National Glucose Awareness Week from Sept. 23-29, 2024.